Growth hormone axis
Tesamorelin
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US.
Quick start
Tesamorelin at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 1–2 mg per administration
- How often
- Every day
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Timing
- Commonly once daily; evening dosing is frequently discussed.
- What people report
- Studied over months for its licensed indication; community timelines run in weeks.
- Time to steady level
- ~3 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- 12+ weeks
- Break between
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C221H366N72O67S
- Mol. weight
- 5,135.9 Da
- CAS
- 218949-48-5
- PubChem CID
- 16137828
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Tesamorelin describe 1–2 mg per administration. Descriptive only, not a recommendation.
Dosing schedule
How Tesamorelin is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Typical blockA stabilised GHRH analog studied at about 2 mg daily. | 1–2 mg | Once daily | SubQ |
What it can be combined with
How Tesamorelin is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- CJC-1295 (DAC)Both are GHRH analogs; combining them duplicates the same signal.Use caution
- CJC-1295 (no DAC)Both are GHRH analogs; combining them duplicates the same signal.Use caution
- SermorelinBoth are GHRH analogs; combining them duplicates the same signal.Use caution
- IpamorelinGHRP plus a stabilised GHRH analog; complementary rather than redundant.Commonly combined
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Tesamorelin visceral-fat study (Falutz et al., NEJM 2007)2 mg daily reduced visceral adipose tissue in research participants.